Search Results
Results found for "Brigitte Kieffer"
- GPCR Collaboration: From Models to Medicine
GPCRs demanded something different: the integration of modeling, medicinal chemistry, and pharmacology ligands, he relies on a network of collaborators worldwide , each bringing specialized expertise in different If docking can suggest binding modes but can’t resolve nanomolar potency differences, they say so.
- Isoforms of GPR35 have distinct extracellular N-termini that allosterically modify...
GPR35 is known to be expressed as two distinct isoforms that differ only in the length of their extracellular N-termini by 31 amino acids, but detailed insights into their functional differences are lacking. thoroughly profile both GPR35 isoforms for constitutive and ligand-induced activation and signaling of 10 different
- 📰 GPCR Weekly News, April 29 to May 5, 2024
We got a little busy with all the major events at Dr.GPCR, so our weekly news looks slightly different
- Chemerin Forms: Their Generation and Activity
discusses the specific tissue expression of the components of the chemerin system, and the role of different Methods of identifying and determining the levels of different chemerin forms in both mass and activity
- AlphaFold2 versus experimental structures: evaluation on G protein-coupled receptors
However, the predicted models and experimental structures were different in many aspects including the These differences impeded the use of predicted structure models in the functional study and structure-based
- The microglial endocannabinoid system similarly regulated by lipopolysaccharide and interferon gamma
Furthermore, we demonstrate that the efficacy of different synthetic cannabinoid treatments with respect This indicates that different pro-inflammatory stimuli influence the capacity of microglia to synthesize
- Disentangling bias between G q, GRK2, and arrestin3 recruitment to the M 3 muscarinic acetylcholine
Different agonists can promote differential receptor-induced signaling responses - termed bias - potentially by eliciting different levels of recruitment of effector proteins. inhibitors of Gi and Gq proteins and analyzed arrestin3 binding to prestimulated M3 receptors to avoid differences We measured substantial differences in the agonist efficacies to induce M3R-arrestin3 versus M3R-GRK2
- Conservation of Allosteric Ligand Binding Sites in G-Protein Coupled Receptors
These sites cluster at nine distinct locations, and each can be found in many different proteins. generally show little or no similarity, and the amino acid residues interacting with these ligands also differ
- Functional modulation of PTH1R activation and signaling by RAMP2
Receptor-activity-modifying proteins (RAMPs) are ubiquitously expressed membrane proteins that associate with different Using different optical biosensors to measure the activation of PTH1R and its downstream signaling, we
- Overview of adhesion GPCRs self-activation
Among the different families of G-protein-coupled receptors (GPCRs), adhesion GPCRs (aGPCRs) represent Different studies have shown that aGPCRs such as Lphns have promiscuous behavior, where in a constitutive state Lphns signal through different types of G proteins, so knowing the factors that determine the Finally a comparative close analysis of the different Cryo-EM receptor structures with Gq, Gs, Gi and G12 showed that Gq/Gs have a similar mode of receptor binding, while Gi/G12 use a different engagement
- Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies
Different strategies, such as antibodies, small chemicals, hormones, cytokines, and, recently, gene editing has shown, in the last decade, increasing evidence of its antitumoral properties in more than a dozen different
- A2A Fluorescent Competitive Binding: Advancing NanoBRET® Target Engagement for GPCR Drug Discovery
Then, the linker composition is optimized, by using different hinges and spacers . A 2A AR tracers (CELT-463 and CELT-464) , bearing the same pharmacophore and fluorophore, but with different As seen in figure 2, a heterogenous set of compounds (agonists and antagonists, different structures
- The Hidden Operating Cadence That’s Actually Driving Your Biotech
A different cadence and a different trajectory. Strategy sets direction. Cadence creates movement.
- Scientific Isolation: The Real Reason Early Biotechs Lose Traction
you as “interesting but unready.” 3️⃣ Internal Alignment Frays When “the science” drives everything, different timelines and decisions It looks good: No one, from intern to CSO, board member, or pharma partner, gives a different
- Unlocking the Future of Medicine: Advancements in GPCR Research
., for their study on Systems modeling of oncogenic G-protein and GPCR signaling reveals unexpected differences Registrants will learn: The powerful applications of new cellular assays to determine GPCR ligand behavior in different Oncology and Immunology Systems modeling of oncogenic G-protein and GPCR signaling reveals unexpected differences
- Identification and functional characterization of the sulfakinin and sulfakinin receptor in the...
The expression levels of the two genes were different between male and female adults, and there were significant changes in different developmental stages, tissues, and between starvation and following
- From Technician to Trailblazer: How Sokhom Pin Designed His Own PhD Program While Working in Industry
But Sokhom’s journey started differently.
- How to Use Statistical Methods to Strengthen Every GPCR Drug Discovery Decision
Terry's Corner – Curve Shifts Don’t Lie, But Your Eyes Might In early drug discovery, “those curves look different analysis that prevents underpowered studies, this module hands you a practical framework to validate differences
- Dynamic recognition of naloxone, morphine and endomorphin1 in the same pocket of µ-opioid receptors
a 1-μs time scale and metadynamics-enhanced conformational sampling are used here to determine the different This finding reveals a dynamic mechanism for the response of MOR to different ligands and provides a
- Early Stage Biotech Hiring: What Really Holds a Team Together When the Science Starts to Drift
The Difference Between Competent and Useful in Early Stage Biotech As uncertainty increases, a subtle Usefulness reveals itself only under pressure. ✅ Recognizing this difference changes how founders evaluate They operate inside it. 👉 This is why early-stage biotech hiring needs a different lens.
- New role of β-arrestins in MOR signaling
Therefore, the study of the different signal transductions triggered by the opioid-receptor interaction proposals is to take advantage of biased agonism, i.e. when the same receptor signals downstream through different signaling pathways triggered by different molecules2. There are several reports that have addressed the differences in the mechanisms of transduction triggered
- Recurrent high-impact mutations at cognate structural positions in class A G protein-coupled ...
Because there are many more GPCRs than effectors, mutations in different receptors could perturb signaling These data suggest that recurrent impactful oncogenic mutations perturb different GPCRs to subvert signaling The possibility that multiple different GPCRs could moonlight as drivers or enablers of a given cancer
- Lack of Oestrogen Receptor Expression in Breast Cancer Cells Does Not Correlate with Kisspeptin...
Interestingly, both cell lines displayed different complements of β-arrestin 1 and 2 expression. Whether this divergence is related to the observed differences in β-arrestin complements warrants further
- The Five Traps of Ignoring Kinetics
But that’s timing, not a different kind of corn. That’s not pharmacology. That’s kinetics. It’s the difference between building a solid pipeline and chasing ghosts.
- GPCRs are not simple on-off switches: deep dive into GPCR-ligand interactions
categorized into four distinct efficacy classes: 1) full agonists produce the maximal response and can differ This variability in drug effects is due to different ligands inducing unique GPCR conformations that to molecular rheostats, capable of sampling a spectrum of conformations with relatively small energy differences
- How a Failed Med School Dream Sparked a GPCR Biotech Revolution
The stakes are different. The pressures are different.
- Your GPCR Program Decisions Depend on Good Data Interpretation
At first glance, when a ligand binds at two different affinities in the same system, it seems logical Every day spent misunderstanding apparent affinity differences delays key milestones. 🗣️ “Thank you
- Odorant receptors – a bit of smell for drug discovery
ORs are highly expressed by olfactory sensory neurons of the nose where they are activated by different Although ORs expression is quite stable, the number of ORs expressed in different human tissues is highly In the immune system ORs are expressed in different blood cells where aroma compounds from butter, known Exploring ORs in drug discovery – opportunities and threats Given the functional relevance of ORs in different
- Transmembrane domains of GPCR dimers – a novel hot spot for drug discovery
GPCR dimers are therefore emerging drug targets in different therapeutic areas including depression, Different models of dimer formation have been described for different receptors such as the ‘rolling
- Why Opposing Processes Matter for Your Next GPCR Drug
Internalized Signaling: Same Receptor, Different Story A GPCR response isn’t always over when the receptor illustrates this with classic β-receptor partial agonists, showing how heart rate set-points under different












